2. Academic Validation
  3. Design and synthesis of unprecedented 9- and 10-membered cyclonucleosides with PRMT5 inhibitory activity

Design and synthesis of unprecedented 9- and 10-membered cyclonucleosides with PRMT5 inhibitory activity

  • Bioorg Med Chem. 2022 Jul 15;66:116820. doi: 10.1016/j.bmc.2022.116820.
Shuhei Kawamura 1,  Rachel L Palte 2,  Hai-Young Kim 3,  Josep Saurí 3,  Christopher Sondey 4,  My S Mansueto 4,  Michael D Altman 2,  Michelle R Machacek 5
Affiliations

Affiliations

  • 1 Discovery Chemistry, Merck & Co., Inc., Boston, MA 02115, United States. Electronic address: shuhei.kawamura@merck.com.
  • 2 Computational and Structural Chemistry, Merck & Co., Inc., Boston, MA 02115, United States.
  • 3 NMR Structure Elucidation, Process and Analytical Chemistry, Merck & Co., Inc., Boston, MA 02115, United States.
  • 4 Quantitative Biosciences, Merck & Co., Inc., Boston, MA 02115, United States.
  • 5 Discovery Chemistry, Merck & Co., Inc., Boston, MA 02115, United States.
PMID: 35594650 DOI: 10.1016/j.bmc.2022.116820
Abstract

Synthesis of medium-sized rings is known to be challenging due to high transannular strain especially for 9- and 10-membered rings. Herein we report design and synthesis of unprecedented 9- and 10-membered purine 8,5'-cyclonucleosides as the first cyclonucleoside PRMT5 inhibitors. The cocrystal structure of PRMT5:MEP50 in complex with the synthesized 9-membered cyclonucleoside 1 revealed its binding mode in the SAM binding pocket of PRMT5.

Keywords

Cyclonucleoside; Medicinal chemistry; Molecular modeling; Nucleoside; PRMT5; PRMT5 inhibitor; X-ray crystallography.

Figures
Products